Since the beginning of this century, advances in understanding the biology of multiple myeloma have transformed the disease ...

For more than a year, Diane Hunter, now 72, had been experiencing vague symptoms—pain in her spine and hips, nausea, ...

For the first time, patients with abnormal cells detected in their bone marrow have a treatment option before the condition ...

The FDA has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) for the treatment of adult patients with high-risk ...

A Stakeholder Interchange convened in Los Angeles, California, by The American Journal of Managed Care explores the treatment ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved belantamab mafodotin-blmf in combination with bortezomib and dexamethasone for the treatment of ...

HDP-101, an ADC, received FDA fast track designation for multiple myeloma, highlighting its potential in addressing unmet medical needs. Phase 1/2a trials show HDP-101's promising efficacy and ...

Following a strong early showing of Tecvayli and Darzalex Faspro in newly diagnosed multiple myeloma patients last month, Johnson & Johnson is making the case for its oncology cocktail as a potential ...

Belantamab mafodotin, a BCMA-targeting ADC, is approved for relapsed/refractory multiple myeloma after two prior therapies, showing significant PFS and OS benefits in the DREAMM-7 trial. The drug ...

Treatment with belantamab mafodotin plus bortezomib and dexamethasone reduced the risk of death by 51% compared with the combination of daratumumab, bortezomib, and dexamethasone. The Food and Drug ...

LOS ANGELES, Oct. 14, 2025 (GLOBE NEWSWIRE) -- It is with great sadness that the International Myeloma Foundation (IMF) shares the news of the death of Dr. Brian G.M. Durie, co-founder of the ...